LAKE FOREST, Calif.,
Jan. 20, 2015 /PRNewswire/
-- Cryoport, Inc. (OTCBB: CYRX) ( "Company"), the leading
provider of advanced cryogenic logistics solutions for life
sciences serving markets including immunotherapies, stem cells,
cell lines, clinical research organizations, vaccine manufacturers
and reproductive medicine, today announced the appointment of
Mark W. Sawicki, Ph.D. as Chief
Commercial Officer of Cryoport Systems.
As Chief Commercial Officer, Dr. Sawicki will lead Cryoport's
global sales and marketing organization. Dr. Sawicki brings broad
experience and proven success in developing new business
opportunities in the life sciences industry, and his
results-oriented approach and sharp business acumen will play a
pivotal role in accelerating Cryoport's track record of growth and
innovation as a leading solutions provider to the life
sciences.
Dr. Sawicki brings fifteen years of business development and
sales management experience, having consistently delivered on
corporate revenue and market share goals in the pharmaceutical and
biotechnology industries. Dr. Sawicki was most recently the
Chief Business Officer at AAIPharma Services Corporation/Cambridge
Major Laboratories Inc.; additionally, he has served in senior
business development roles at CMC Biologics and at Albany Molecular
Research Inc. (AMRI), where he increased revenue at rates far
outpacing industry standards.
Dr. Sawicki holds a Bachelor of Science in Biochemistry from the
State University of New York at Buffalo and a Ph.D. in Biochemistry
from the State University of New York at
Buffalo, School of Medicine and Biomedical Sciences. He also
received graduate training at the Hauptman Woodard Medical Research
Institute. Dr. Sawicki has authored a dozen scientific publications
in drug discovery with a focus on oncology and immunology.
"I am delighted to welcome Mark to Cryoport. We look forward to
drawing from his thoughtful insights and dynamic leadership skills
to further the development of our business. His knowledge of the
life sciences industry and mastery in solutions selling and
marketing will elevate our cryogenic logistics solutions in the
marketplace. Mark's client-centric reputation is quite valuable to
Cryoport's clients who are seeking a competitive advantage with
reliability, efficiency and effectiveness," commented Jerrell Shelton, CEO of Cryoport.
Dr. Sawicki stated, "I look forward to working with my new
colleagues at Cryoport as we develop and execute on sales and
marketing strategies designed to accelerate growth and provide our
clients with comprehensive solutions and best-in-class customer
service. I look forward to identifying and evaluating new business
opportunities for the Company. Cryoport provides vital, enabling
solutions to the development of the life sciences industry and is
in a unique and enviable position. The Company supports a wide
diversity of clients, but as novel biological therapies, which
include CAR T cells, regenerative medicine, tissue engineering and
patient based immunotherapies, constitute an ever-increasing
share of new drug development, 'chain of custody' and 'chain of
condition' are developing into mandatory regulations. Cryoport's
relationships with the three largest shipping companies in the
world further validate the advantages of its outsourced solutions
and regulatory support capabilities in support of global resourcing
needs. I feel privileged to be a part of this dynamic Company's
future and will endeavor to provide effective leadership to our
sales and marketing efforts and Companywide."
Richard Rathmann, Chairman of the
Board of Cryoport, said, "Mark is a great addition to Cryoport. Our
customers, as well as the entire Cryoport team, will benefit from
his positive energy and thoughtful approach. Combine these personal
attributes with Mark's extensive experience in the life sciences,
and he is well-positioned to capitalize on Cryoport's momentum and
maximize the tremendous growth opportunities ahead."
About Cryoport, Inc.
Cryoport provides leading edge
frozen logistics solutions to the life sciences industry through
the combination of purpose-built proprietary packaging, information
technology and specialized cold chain logistics expertise. Its
competencies range from skilled, total turnkey management of the
entire life sciences cold chain logistics process to complex total
management solutions for outsourced cold chain logistics.
Its packaging, built around its Cryoport Express® liquid
nitrogen dry vapor shippers, is validated to maintain a constant
-150°C temperature for a 10-plus day dynamic shipment duration. Its
information technology boast a Cryoportal™ Logistics Management
Platform which manages the entire shipment process, including
initial order input, document preparation, customs clearance,
integrator/courier management, shipment tracking, issue resolution,
and delivery. Cryoport uses recyclable and reusable components
providing an environmentally friendly solution. Cryoport solutions
can record the "chain of condition" and "chain of custody" for
shipments thereby meeting the exacting requirements for scientific
work and for regulatory purposes. For more information, visit
www.cryoport.com.
Forward Looking Statements
Statements in this news
release which are not purely historical, including statements
regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the company's cash flow, market acceptance risks, and
technical development risks. The company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the company's SEC reports including,
but not limited to, the annual report on Form 10-K for the year
ended March 31, 2013. The company
cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cryoport-appoints-mark-w-sawicki-as-chief-commercial-officer-to-lead-sales-and-marketing-team-300022076.html
SOURCE Cryoport, Inc.